132 related articles for article (PubMed ID: 33353870)
1. Pathology grade influences competing mortality risks in elderly men with prostate cancer.
Alam MU; Kumar J; Norez D; Tanneru K; Jazayeri SB; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Gautam S; Balaji KC
Urol Oncol; 2021 Aug; 39(8):493.e1-493.e7. PubMed ID: 33353870
[TBL] [Abstract][Full Text] [Related]
2. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
4. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
5. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
6. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.
Lee JY; Cho KS; Kwon JK; Jeh SU; Kang HW; Diaz RR; Ham WS; Koom WS; Keum KC; Choi YD
Ann Surg Oncol; 2014 Nov; 21(12):4026-33. PubMed ID: 24841351
[TBL] [Abstract][Full Text] [Related]
7. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.
Pashtan I; Chen MH; D'Amico AV
Cancer Epidemiol; 2014 Oct; 38(5):613-8. PubMed ID: 25164550
[TBL] [Abstract][Full Text] [Related]
8. Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death.
Huynh MA; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
Eur Urol; 2016 Jun; 69(6):976-9. PubMed ID: 26388503
[TBL] [Abstract][Full Text] [Related]
9. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
[TBL] [Abstract][Full Text] [Related]
10. Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study.
Song P; Yang B; Peng Z; Zhou J; Ren Z; Fang K; Yang L; Wang L; Dong Q
Int J Surg; 2020 Apr; 76():64-68. PubMed ID: 32109649
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of pathologically localized high-grade prostate cancer treated with radical prostatectomy.
Heo JE; Park JS; Lee JS; Kim J; Jang WS; Rha KH; Choi YD; Hong SJ; Ham WS
Medicine (Baltimore); 2019 Oct; 98(42):e17627. PubMed ID: 31626145
[TBL] [Abstract][Full Text] [Related]
12. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
14. Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI.
Chandra RA; Chen MH; Zhang D; Loffredo M; D'Amico AV
Clin Genitourin Cancer; 2015 Aug; 13(4):400-405. PubMed ID: 25862319
[TBL] [Abstract][Full Text] [Related]
15. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
17. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
18. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
[TBL] [Abstract][Full Text] [Related]
20. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
Vatandoust S; Kichenadasse G; O'Callaghan M; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis CS; Moretti K
BJU Int; 2018 May; 121 Suppl 3():48-54. PubMed ID: 29603585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
